Rznomics Inc.

📍 성남시, South Korea🗓 Founded 2017👥 10 employees💰 Last funded Mar 2022
Research Services
LinkedIn
Rznomics is developing safe and effective biopharmaceuticals in oncology, degenerative disease, and genetic disease based on RNA platform technology called trans-splicing ribozyme. Acknowledged by bio-focused institutions, Rznomics has raised \23.7 billion from series A& B and recently raised \37.2 billion from series C, resulting in a total of \60.9 billion of fundraising. Also, Rznomics received \8 billion for the new drug development research funding from the government. In 2022 1H, Rznomics’ RZ-001 IND submission for the HCC treatment was approved by MFDS, and the clinical trial for the RZ-001 is currently running. In addition to the RZ-001, Rznomics has competitive and innovative pipelines, such as glioblastoma multiforme, Alzheimer’s disease, genetic ocular disease (retinitis pigmentosa), and circular RNA technology. Rznomics is also actively partnering with global companies to discuss collaboration opportunities in co-research, co-development, and licensing.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2017
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Korea
1
Frequently asked questions
Who invested in Rznomics Inc.?
Rznomics Inc. has 1 investors on record on gritt.io, 1 mid-stage.
When did Rznomics Inc. last raise funding?
The most recent investment in Rznomics Inc. recorded on gritt.io was in March 2022.
When was Rznomics Inc. founded?
Rznomics Inc. was founded in 2017.
What industry is Rznomics Inc. in?
Rznomics Inc. operates in Research Services. Find similar Research Services investors on gritt.io.
Where is Rznomics Inc. based?
Rznomics Inc. is headquartered in 성남시, South Korea.